Max Meyrath

This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.

This study discovers potent, selective macrocyclic peptide ligands for CXCR4, a class A GPCR, demonstrating the feasibility of de novo peptide design for this receptor family.

This study shows ACKR3 is released on extracellular vesicles under both basal and ligand-induced conditions, sequestering chemokines and opioid peptides and modulating their signaling.

This study reveals an atypical activation mechanism of CXCR7, identifies its role as an opioid receptor, and highlights potential for novel pain therapeutics.

This study characterizes VUF16840 as a selective inverse agonist of ACKR3 that inhibits constitutive and chemokine-induced signaling by stabilizing the inactive conformation of the receptor.

This study identifies GPR182/ACKR5 as a scavenger receptor for CXCL17, GPR15L, and endogenous peptides, revealing distinct binding modes and expanding its ligand repertoire beyond classical chemokines.